SCHEMBL2437982

SCHEMBL2437982

COc1ccccc1C(=O)Nc1noc2cccc(OCC(F)(F)F)c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.49
RAB9A P51151 3/20 0.47
RXFP1 Q9HBX9 2/20 0.46
KCNA5 P22460 1/20 0.45
KCNK3 O14649 3/20 0.45
KCNK9 Q9NPC2 3/20 0.45
TP53 P04637 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
NPC1 O15118 2/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
KMT2A Q03164 1/20 0.44
LCLAT1 Q6UWP7 1/20 0.44
NCS1 P62166 1/20 0.43
BRD4 O60885 1/20 0.42
SGMS1 Q86VZ5 1/20 0.42
SGMS2 Q8NHU3 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2441287 0.88 SMN1; SMN2 (0.43) RAB9ARXFP1TP53SMN1; SMN2NPC1
SCHEMBL2474206 0.86 KCNK3 (0.58) RAB9ARXFP1KCNA5KCNK3KCNK9
SCHEMBL2439122 0.85 UGCG (0.43) S1PR1RXFP1KCNK3KCNK9TP53
SCHEMBL2440193 0.84 TP53 (0.52) RAB9ARXFP1KCNA5KCNK3KCNK9
SCHEMBL2441155 0.83 UGCG (0.41) TP53SMN1; SMN2LCLAT1SGMS1SGMS2
SCHEMBL2440435 0.82 LCLAT1 (0.43) S1PR1KCNK3KCNK9TP53SMN1; SMN2
SCHEMBL2438849 0.82 SMN1; SMN2 (0.45) RAB9AKCNA5TP53SMN1; SMN2NPC1
SCHEMBL2439200 0.81 PYGL (0.43) RAB9ATP53SMN1; SMN2NPC1ALDH1A1
SCHEMBL2442656 0.80 KCNA5 (0.40) KCNA5TP53SMN1; SMN2MEN1KMT2A
Cyclopropane SCHEMBL2441865 0.80 KCNA5 (0.39) KCNA5TP53SMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893589-B1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS GRUENENTHAL GMBH (DE) 2011-09-14 EP claimed
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof GRUENENTHAL GMBH (DE) 2008-12-18 US claimed
EP-1893589-B1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS GRUENENTHAL GMBH (DE) 2011-09-14 EP disclosed
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed
EP-1893589-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2008-03-05 EP disclosed
WO-2006131296-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof HTR5A, NPY5R, GRM5 S1PR1 655/4885RAB9A 1962/4885RXFP1 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.